.JPG)
A Partnership for Advancing Type 1 Diabetes Research and Treatment
The Breakthrough T1D U-M–OHSU Cardio-Renal Center of Excellence is a collaborative research and clinical innovation hub focused on preventing and treating heart and kidney complications in people living with type 1 diabetes (T1D). Supported by more than $2.8 million over three years from Breakthrough T1D (formerly JDRF), the Center brings together the University of Michigan and Oregon Health & Science University to accelerate the development of more effective, personalized therapies for T1D-related complications.
Building on more than five years of foundational research at the University of Michigan, the joint Center advances an innovative clinical trial platform designed to rapidly test promising heart and kidney therapies in people with T1D—an area where treatment options remain limited.
Led by Drs. Matthias Kretzler (University of Michigan), and Rodica Pop-Busui (Oregon Health & Science University), the Center integrates precision medicine, real-world clinical data, and multidisciplinary expertise to ensure the right treatment reaches the right person at the right time.
Our Mission and Vision for T1D Care
We are dedicated to transforming the landscape of Type 1 Diabetes treatment. Our vision is to pioneer personalized approaches that address both heart and kidney complications, enhancing patient outcomes and quality of life.
T1D Diabetic Kidney Disease (DKD) outcome and molecular stratification biomarkers
T1D Diabetic Kidney Disease (DKD) outcome and molecular stratification biomarkers are emerging for the early identification of key pathways driving progression of DKD in T1D.
DKD biomarkers have been developed to encompass tubular function and injury, vascular stress and inflammation and tissue fibrosis, the main features of DKD pathobiology. These markers are not only indicators of early signs of DKD but also predictors of DKD progression (e.g., decline in glomerular filtration rate (GFR) and kidney failure) in T1D.
Revolutionizing Treatment for Type 1 Diabetes
With state-of-the-art clinical and research infrastructure and a strong track record of integrating research directly into patient care, the partnership is uniquely positioned to translate scientific discoveries into meaningful health outcomes.
As one of only five Breakthrough T1D Centers of Excellence worldwide, the U-M–OHSU Cardiorenal Center is part of a global effort to accelerate life-improving breakthroughs—and ultimately cures—for people living with type 1 diabetes.
A Platform for Clinical Trials
Our clinical trials aim to revolutionize treatment for Type 1 Diabetes by focusing on personalized approaches. We are committed to improving outcomes for patients with heart and kidney complications.
Trial Objectives
To assess the effectiveness of precision medicine in managing T1D complications.
Expected Outcomes
Enhanced patient health and reduced complications through tailored treatment strategies.
Moving knowledge to application in precision medicine from UMCoE to the UM-OHSU CoE
Our significant milestones in advancing Type 1 Diabetes research. Each achievement represents our commitment to improving patient outcomes.
2017
UMCoE Phase I Launch
In 2017, we launched the Breakthrough T1D (formerly JDRF) Center of Excellence at the University of Michigan. This marked a pivotal moment in our research journey.
2022
First Results Released
In 2022, we shared our initial findings with the community. These results showcased the potential of our personalized treatment approaches.
2023
Expanded Research Focus
In 2023, we expanded our research to include additional complications. This initiative aims to enhance the understanding and treatment of T1D.
2025
Phase 2 Award
COE phase 2 awarded to advance care of T1D cardio-renal complications using precision medicine approaches.
Future
Next Steps Ahead
Looking ahead, we are committed to further innovations and partnering with top pharma institutions in T1D research. Stay tuned for upcoming milestones and breakthroughs.
